Reflections on two consensus documents about chronic kidney disease  by Martínez-Castelao, Alberto et al.
0120-4912 @ 2015 Sociedad Española de Nefrología. Published by ELSEVIER ESPAÑA, SLU. Published under the terms of the CC BY-NC-ND 
Licence (http://creativecommons.org/licenses/by-nc-nd/4.0).
NEFROLOGIA 2015; 35(2):127-130
Revista de la Sociedad Española de Nefrología
www.revistanefrologia.com
Introduction and Background
According to data from the EPIRCE1 (epidemiology of chronic 
renal disease in Spain) research study, chronic kidney disease 
(CKD) affects up to 9.2% of the Spanish population, 6.8% of 
which have advanced-stage disease, including prior definition 
of chronic renal failure (CRF) or estimated glomerular filtra-
tion rate (GFR) of <60 ml/min/1.73 m2.
The Spanish Society of Nephrology (SEN) has been con-
cerned about this major epidemiological problem for years, 
which, in its most advanced stage (stage 5 CKD in renal 
replacement therapy [RRT]), accounts for 2.5% of the total 
Spanish health budget.  The SEN has therefore created a spe-
cific working group, known as the Strategic Action Group, for 
the purpose of continuously monitoring this problem and 
establishing contacts with other scientific societies to adopt 
and improve the multidisciplinary approach to this serious 
public health challenge.  
In 2006 the consensus document for appropriate calcula-
tion of GFR was therefore published jointly with the Spanish 
Society of Clinical Chemistry2 (SEQC), and in 2007 the first 
consensus document for CKD management was prepared 
jointly with the Spanish Society for Family and Community 
Medicine3 (semFYC).
SEN also created a specific working group for the creation 
of “Strategies in Renal Health”, which were then reported to 
the Ministry of Health.  These strategies were also discussed 
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The consensus document from the ten societies7 rep-
resents a multidisciplinary approach from societies that are 
in some way involved in CKD patient management: primary 
care, cardiology, diabetes, endocrinology, internal medicine, 
and SEN itself.  Others are involved in the laboratory diagno-
sis of CKD, as is the case of SEQC.  Beyond the current discus-
sion about how we should diagnose CKD11, it is the 
multidisciplinary nature and the publication of this document 
further afield than our journal which have led to the trans-
versal transmission of current knowledge on the diagnosis 
and management of the most important aspects of our spe-
ciality.  This facilitates its appropriate implementation in 
general clinical practise (and not merely in other specialties) 
while increasing awareness of its earliest stages. Thanks to 
these initiatives, other specialities as diverse as vascular sur-
gery or anaesthesiology are incorporating nephrological 
awareness into their clinical practice in their leading jour-
nals12,13. For the first time, this document successfully united 
the highest number of scientific societies in our field in Spain 
and obtained their consensus on the basic aspects of CKD 
diagnosis, prevention and treatment.  
 1.  The document focuses on the diverse methods of GRF 
measurement, recommending CKD diagnosis through GRF 
estimations based on the CKD-EPI formula (just like the 
KDIGO document on general patient management with 
CKD) and the determination of the albumin/creatinine 
ratio (ACR) in an isolated sample of early morning urine. 
It uses the same categorisation as CKD, taking into account 
the kidney function stage according to GFR measurement 
and ACR in urine, following the KDIGO classification of A1, 
A2 or A3, depending on the intensity of albuminuria.  It 
recommends referring to “elevated urinary albumin excre-
tion” instead of the term “microalbuminuria”, and also the 
term “proteinuria” for urinary elimination of 300 mg/day 
or higher.   
and communicated to other scientific societies at a meeting 
in Madrid in 2008 and published on two occasions in the 
medical journal “Nefrología”4,5.
As proteinuria is a marker of kidney injury and its increase 
a sign of progression towards advanced stages of CKD, the 
creation and publication of the document with recommenda-
tions for the detection and monitoring of proteinuria in CKD6 
was promoted in 2011 by SEN and SEQC. 
The presence of CKD in our general population has been 
increasing, and our approach needs to be updated  based on 
current criteria.  Therefore, SEN, in collaboration with another 
nine scientific societies, assembled a group of experts repre-
senting each of the societies involved (two per society).  In 
December 2012, the first draft was ready of the “Consensus 
Document by ten societies for the detection and management 
of chronic kidney diseases”. The document was initially pub-
lished on the web site of each of the societies, where it was 
submitted for public review. The final document was sent to 
all the societies with the comments received and was again 
published on the respective web sites. It was finally published 
in “Nefrología” last March7.
Over the last three years, the Kidney Disease Improving Global 
Outcomes (KDIGO) initiative has simultaneously published 
guidelines on general management and blood pressure con-
trol in patients with CKD8,9.  Its most relevant contents were 
integrated and summarised in the “SEN document on the 
KDIGO guidelines for the evaluation and treatment of CKD”, 
recently published in “Nefrología”10.
Judging by the number of website visits to the journal 
“Nefrología”, both documents are the object of a high number 
of consultations. Since its online publication on 6th March 
2014, the “Consensus Document by ten societies for the 
detection and management of chronic kidney diseases”7 has 
received 5,223 visits, and the “SEN document on the KDIGO 
guidelines for the evaluation and treatment of CKD”10 has 
had 5,282 visits. In both cases, these are the most visited 
articles in the past year and they triple or quadruple the 
average number of visits to the “Nefrología” journal articles, 
which may represent the multidisciplinary interest in docu-
ments that are being consulted by specialties other than 
nephrology. 
Why were so many consensus documents 
on CKD promoted by SEN? (Table 1)
In view of the fact that both reference documents on CKD 
were promoted by SEN and published sequentially, our aim 
in this edition is to comment upon the specific or differenti-
ating aspects of said documents. 
Both are similar in length: the first consists of 20 pages, 
which contain 7 tables, 2 figures, and 77 bibliographical ref-
erences; meanwhile, the second has 15 pages, 7 tables, 2 fig-
ures, and 45 bibliographical references.
If we analyse the contents of both documents, we note that 
they agree on all essential aspects and there are no discrep-
ancies with regards to content or recommendations. 
There are, however, different minor nuances, which we 
will comment upon. 
Table 1 – Key documents on chronic kidney disease
Document Authors (reference) Year
EPIRCE Otero et al.1 2005
SEN-SEQC Consensus 
document
Gracia et al.2 2006
Strategies for Renal Health Alcázar, de Francisco4 2006
SEN-semFYC Consensus 
document
Alcázar et al.3 2008
Strategies for Renal Health Martínez Castelao5 2009
Proteinuria Recommendations Montañés et al.6 2011
KDIGO-CKD KDIGO-CKD Working Group8 2013
KDIGO-CKD
KDIGO-BPKDIGO BP KDIGO BP Working Group9 2012
10 societies consensus 
document 
Martínez Castelao et al.7 2014
SEN document on KDIGO 
guidelines
Gorostido et al.10 2014
EPIRCE: Epidemiology of chronic renal disease in Spain; CKD: chronic 
kidney disease; SEN: Spanish Society of Nephrology; SEQC: Spanish 
Society of Clinical Chemistry; semFYC: Spanish Society for Family 
and Community Medicine; KDIGO: Kidney Disease Improving Global 
Outcomes; BP: Blood Pressure; CKD: Chronic Kidney Disease.
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guidelines make recommendations for the management and 
treatment of CKD following a systematic evaluation procedure 
of the existing evidence, using the level of recommendation 
according to the GRADE system (Grading of Recommendations 
Assessment, Development and Evaluation).  Very little grade 1 
evidence exists, and the different aspects that create uncer-
tainty are discussed.  The data in the consensus document of 
the ten societies was not presented in this manner.
In short, the ten societies’ document7 adapts the recom-
mendations of the KDIGO10 document to the reality of our 
setting, with several specific recommendations. 
It is SEN’s intention to periodically include scientific evi-
dence as it is generated, updating clinical practice recommen-
dations and existing consensus documents, while evaluating 
international documents resulting from the multi-factorial 
and multidisciplinary approach to the management of 
patients with chronic kidney disease.
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